Ridgetech Inc. (RDGT): Financial results for FY2026

Ridgetech Inc. (RDGT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Ridgetech, Inc. Reports Fiscal Year 2026 Financial Results HANGZHOU, China, July 31, 2026 /PRNewswire/ -- Ridgetech, Inc. (Nasdaq: RDGT) (“Ridgetech” or the “Company”), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced

Event · Earnings
Original reporting
Published Jul 31, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 7:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RDGT
Bearish
medium confidence
Mentioned
$RDGT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 6-K
Decision brief

The 30-second read

$RDGTBearishMed
01

Why it matters

The earnings release provides the first public view of post‑acquisition performance, showing mixed results.

02

Market read

RDGT's FY2026 results signal operational transition risks and opportunities for China pharma distributors.

03

What to watch

Improved cash balance and expanded digital footprint could offset short‑term earnings weakness.

Relevance 7/10Novelty 7/10Timing: post-market July 31 2026 release

Background

Ridgetech transitioned to a wholesale‑focused model, acquiring Allright and divesting retail stores.

Company-level read

Ticker impact

$RDGTBearishMedium confidence
Context

FY2026 earnings show 10.2% revenue growth to $132.2M but a net loss of $1.25M versus prior year profit.

Expected impact

Potential short-term downside pressure with limited upside unless guidance improves.

Evidence & confidence

Loss reversal and modest revenue growth suggest weak earnings momentum; investors may sell.

Market effects

Highlights shift toward online wholesale in Chinese pharma distribution, offline decline.

May influence sentiment on China healthcare logistics and related peers.

Limited global impact; primarily relevant to China‑focused investors.

Counterpoint

Loss could be temporary as online platform scales; revenue growth may support a rebound.

Key entities

  • Ridgetech Inc.

    Nasdaq‑listed Chinese wholesale distributor of pharmaceutical products.

  • Allright (Hangzhou) Internet Technology Co. Ltd

    Online wholesale platform acquired by Ridgetech.

Related articles

$RDGTMed

Ridgetech, Inc. Reports Fiscal Year 2026 Financial Results

Ridgetech, Inc. (Nasdaq: RDGT) reported fiscal year 2026 results for the year ended March 31, 2026. Revenue rose 10.2% to $132.16 million, driven by a full year of Allright’s online platform after its Feb. 28, 2025 acquisition. Gross profit increased 23.8% to $4.75 million, but net loss was $1.25 million versus net income $10.20 million a year earlier.

$NVDAHighAI 9/10

What's Going On With Nvidia Stock Wednesday

Nvidia (NVDA) reported quarterly earnings of $2.68 per share on revenue of $115.84 billion, beating estimates. Data center sales reached $107.6 billion. The company raised its revenue forecast for the current quarter and long-term growth outlook, but expects no revenue from China. Nvidia also expanded its stock buyback program.

$DISMedAI 8/10

Disney’s Experiences Segment Hit Record Quarterly Revenue of $10.1 Billion as Cruise Days Surged. Can the Momentum Last?

Disney (DIS) reported Q4 2026 revenue of $25.95B, up 16% YoY, with its Experiences segment hitting a record $10.1B. All units grew, with Experiences leading in operating income at $2.25B. Adjusted net income rose 56% to $3.35B, beating estimates. The company plans to invest $60B in Experiences over a decade, focusing on parks and cruises.

$GLADMed

Gladstone Capital (GLAD) Q4 2026 Earnings Call Transcript

Gladstone Capital (GLAD) reported Q4 2026 earnings with net interest margin at 8.2%. Fee income was below average, but incentive fee credit covered 100% of regular distributions. Net asset value declined to $20.77 per share due to unrealized depreciation and a supplemental distribution. Total investment income rose 11.7% for the year, covering distributions at 104.5%. The company discussed its investment strategy and credit management, highlighting its focus on the lower middle market.